SG11201811737SA - Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease - Google Patents
Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney diseaseInfo
- Publication number
- SG11201811737SA SG11201811737SA SG11201811737SA SG11201811737SA SG11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA SG 11201811737S A SG11201811737S A SG 11201811737SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indianapolis
- ethoxy
- amino
- indiana
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 3
- 229930195729 fatty acid Natural products 0.000 title abstract 3
- 239000000194 fatty acid Substances 0.000 title abstract 3
- -1 fatty acid modified urocortin-2 analogs Chemical class 0.000 title abstract 3
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 abstract 1
- 230000021736 acetylation Effects 0.000 abstract 1
- 238000006640 acetylation reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 230000011987 methylation Effects 0.000 abstract 1
- 238000007069 methylation reaction Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362711P | 2016-07-15 | 2016-07-15 | |
| US201662431682P | 2016-12-08 | 2016-12-08 | |
| US201762491385P | 2017-04-28 | 2017-04-28 | |
| PCT/US2017/041922 WO2018013803A1 (fr) | 2016-07-15 | 2017-07-13 | Nouveaux analogues d'urocortine-2 modifiés par acides gras pour le traitement du diabète et de maladies rénales chroniques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811737SA true SG11201811737SA (en) | 2019-01-30 |
Family
ID=59501524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811737SA SG11201811737SA (en) | 2016-07-15 | 2017-07-13 | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10894817B2 (fr) |
| EP (1) | EP3484495B1 (fr) |
| JP (1) | JP2019525919A (fr) |
| KR (1) | KR20190017982A (fr) |
| CN (1) | CN109475592B (fr) |
| AU (1) | AU2017295708B2 (fr) |
| BR (1) | BR112018076693A2 (fr) |
| CA (1) | CA3030965C (fr) |
| CL (1) | CL2019000043A1 (fr) |
| CO (1) | CO2018014026A2 (fr) |
| CR (1) | CR20190015A (fr) |
| DO (1) | DOP2019000007A (fr) |
| EC (1) | ECSP19003047A (fr) |
| ES (1) | ES2901477T3 (fr) |
| IL (1) | IL264025A (fr) |
| JO (1) | JOP20170153A1 (fr) |
| MA (1) | MA45673A (fr) |
| MX (1) | MX2019000661A (fr) |
| PE (1) | PE20190470A1 (fr) |
| PH (1) | PH12019500074A1 (fr) |
| SG (1) | SG11201811737SA (fr) |
| SV (1) | SV2019005808A (fr) |
| TW (1) | TW201811821A (fr) |
| WO (1) | WO2018013803A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| MD3436461T2 (ro) | 2016-03-28 | 2024-05-31 | Incyte Corp | Compuși pirolotriazină ca inhibitori TAM |
| SI3687996T1 (sl) | 2017-09-27 | 2022-04-29 | Incyte Corporation | Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM |
| WO2019140023A1 (fr) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| WO2019140024A1 (fr) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| WO2019140021A1 (fr) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| WO2019140030A1 (fr) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| WO2019140025A1 (fr) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Polythérapie |
| MD3813800T2 (ro) | 2018-06-29 | 2025-10-31 | Incyte Corp | Formulări de inhibitor al AXL/MER |
| US20200027555A1 (en) * | 2018-07-17 | 2020-01-23 | Lewis Pharmaceutical Information, Inc. | Patient centric drug analysis platform |
| EP4114401A1 (fr) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1 |
| JP7832927B2 (ja) * | 2020-08-19 | 2026-03-18 | サノフイ | Ｃｒｆ２受容体アゴニスト及び治療におけるその使用 |
| WO2022159395A1 (fr) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles métaboliques et hépatiques |
| WO2023285334A1 (fr) * | 2021-07-12 | 2023-01-19 | Novo Nordisk A/S | Nouveaux dérivés d'urocortine 2 modifiés par un acide gras et leurs utilisations |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| EP4234574A1 (fr) | 2022-02-23 | 2023-08-30 | Corteria Pharmaceuticals | Agonistes du récepteur crf2 et leur utilisation en thérapie |
| WO2025104264A1 (fr) * | 2023-11-17 | 2025-05-22 | Gubra A/S | Polypeptides sélectifs de hcrhr2 |
| WO2025106761A1 (fr) * | 2023-11-17 | 2025-05-22 | Eli Lilly And Company | Composés pour le traitement du diabète ou de l'obésité |
| WO2026064486A1 (fr) * | 2024-09-20 | 2026-03-26 | Neurocrine Biosciences, Inc. | Peptides chimiquement modifiés et leur utilisation |
| WO2026064495A1 (fr) * | 2024-09-20 | 2026-03-26 | Neurocrine Biosciences, Inc. | Peptides chimiquement modifiés et leur utilisation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0724637T4 (da) | 1994-06-14 | 2002-09-16 | Neurocrine Biosciences Inc | Kortikotropinfrigørende faktor2-receptorer |
| EP0845035A2 (fr) * | 1995-06-13 | 1998-06-03 | The Salk Institute For Biological Studies | Peptides d'urocortine |
| US20040034882A1 (en) | 1999-07-15 | 2004-02-19 | Vale Wylie W. | Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| DK1305334T3 (da) * | 2000-08-04 | 2009-02-02 | Res Dev Foundation | Urocortinproteiner og anvendelser deraf |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6812210B2 (en) | 2001-03-15 | 2004-11-02 | Research Development Foundation | Urocortin-III and uses thereof |
| US7192924B2 (en) * | 2002-01-16 | 2007-03-20 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| GR1004664B (en) | 2002-11-26 | 2004-09-02 | Bionature E A Ltd | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
| WO2005103690A2 (fr) | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2) |
| CA2576435A1 (fr) | 2004-08-09 | 2006-03-23 | Research Development Foundation | Modulateurs de recepteurs couples a la proteine g b1 fondes sur une structure |
| KR20070112155A (ko) | 2005-02-08 | 2007-11-22 | 리서치 디벨럽먼트 파운데이션 | 가용성 Ｇ-단백질 연결 수용체(ｓＧＰＣＲ)와 관련된조성물 및 방법 |
| US7815905B2 (en) | 2006-01-27 | 2010-10-19 | Research Development Foundation | Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors |
| US7982018B2 (en) * | 2006-10-16 | 2011-07-19 | Conjuchem, Llc | Modified corticotropin releasing factor peptides and uses thereof |
| WO2008157302A2 (fr) | 2007-06-13 | 2008-12-24 | Research Development Foundation | Procédés pour le traitement et la prévention de tauopathies et l'amyloïdose de bêta-amyloïde en modulant la signalisation de récepteur crf |
| SG171957A1 (en) | 2008-11-04 | 2011-07-28 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
| WO2011025905A1 (fr) | 2009-08-28 | 2011-03-03 | Research Development Foundation | Analogues d'urocortine 2 et leurs utilisations |
| US20110105397A1 (en) | 2009-11-04 | 2011-05-05 | Gengo Peter J | Method for treating heart failure with stresscopin-like peptides |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (fr) | 2010-02-02 | 2014-10-15 | Novartis AG | Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf |
| WO2013063046A1 (fr) | 2011-10-24 | 2013-05-02 | Research Development Foundation | Procédés d'augmentation de la sécrétion d'insuline par costimulation des récepteurs du facteur de libération de la corticotropine |
| WO2015150914A2 (fr) | 2014-04-03 | 2015-10-08 | The Regents Of The University Of California | Administration systémique de vecteurs de virus codant pour l'urocortine-2 et gènes associés pour traiter un dysfonctionnement cardiaque lié au diabète et une insuffisance cardiaque congestive |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| WO2017220706A1 (fr) * | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Compositions pharmaceutiques de dérivés de fgf21 et leurs utilisations |
-
2017
- 2017-06-29 JO JOP/2017/0153A patent/JOP20170153A1/ar unknown
- 2017-06-30 TW TW106121914A patent/TW201811821A/zh unknown
- 2017-07-13 PE PE2019000060A patent/PE20190470A1/es unknown
- 2017-07-13 CR CR20190015A patent/CR20190015A/es unknown
- 2017-07-13 EP EP17746231.4A patent/EP3484495B1/fr active Active
- 2017-07-13 ES ES17746231T patent/ES2901477T3/es active Active
- 2017-07-13 AU AU2017295708A patent/AU2017295708B2/en not_active Ceased
- 2017-07-13 BR BR112018076693-3A patent/BR112018076693A2/pt not_active Application Discontinuation
- 2017-07-13 MA MA045673A patent/MA45673A/fr unknown
- 2017-07-13 WO PCT/US2017/041922 patent/WO2018013803A1/fr not_active Ceased
- 2017-07-13 SG SG11201811737SA patent/SG11201811737SA/en unknown
- 2017-07-13 MX MX2019000661A patent/MX2019000661A/es unknown
- 2017-07-13 CN CN201780043923.7A patent/CN109475592B/zh active Active
- 2017-07-13 KR KR1020197001249A patent/KR20190017982A/ko not_active Withdrawn
- 2017-07-13 CA CA3030965A patent/CA3030965C/fr active Active
- 2017-07-13 JP JP2019501685A patent/JP2019525919A/ja not_active Withdrawn
- 2017-07-13 US US15/648,542 patent/US10894817B2/en active Active
-
2018
- 2018-12-21 CO CONC2018/0014026A patent/CO2018014026A2/es unknown
- 2018-12-30 IL IL264025A patent/IL264025A/en unknown
-
2019
- 2019-01-07 CL CL2019000043A patent/CL2019000043A1/es unknown
- 2019-01-10 DO DO2019000007A patent/DOP2019000007A/es unknown
- 2019-01-11 PH PH12019500074A patent/PH12019500074A1/en unknown
- 2019-01-11 SV SV2019005808A patent/SV2019005808A/es unknown
- 2019-01-15 EC ECSENADI20193047A patent/ECSP19003047A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10894817B2 (en) | 2021-01-19 |
| EP3484495B1 (fr) | 2021-09-08 |
| SV2019005808A (es) | 2019-04-04 |
| EP3484495A1 (fr) | 2019-05-22 |
| CN109475592A (zh) | 2019-03-15 |
| CO2018014026A2 (es) | 2019-01-18 |
| MA45673A (fr) | 2021-05-26 |
| ECSP19003047A (es) | 2019-01-31 |
| BR112018076693A2 (pt) | 2019-04-02 |
| CA3030965A1 (fr) | 2018-01-18 |
| CL2019000043A1 (es) | 2019-06-07 |
| JOP20170153A1 (ar) | 2019-01-30 |
| WO2018013803A1 (fr) | 2018-01-18 |
| AU2017295708B2 (en) | 2019-05-09 |
| KR20190017982A (ko) | 2019-02-20 |
| MX2019000661A (es) | 2019-05-15 |
| US20180016318A1 (en) | 2018-01-18 |
| DOP2019000007A (es) | 2019-04-15 |
| IL264025A (en) | 2019-01-31 |
| CA3030965C (fr) | 2022-04-26 |
| JP2019525919A (ja) | 2019-09-12 |
| TW201811821A (zh) | 2018-04-01 |
| ES2901477T3 (es) | 2022-03-22 |
| AU2017295708A1 (en) | 2018-12-20 |
| PE20190470A1 (es) | 2019-04-04 |
| PH12019500074A1 (en) | 2019-07-29 |
| CN109475592B (zh) | 2022-08-09 |
| CR20190015A (es) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811737SA (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201810834WA (en) | Hepatitis b antiviral agents | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201907232XA (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201807543YA (en) | Hepatitis b antiviral agents | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408511QA (en) | Liquid preparations of amines and organic acids stabilized by salts | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes |